Barclays analyst Matt Miksic upgraded ZimVie (ZIMV) to Equal Weight from Underweight with a price target of $19, up from $9, after the company agreed to be taken private by Archimed for $19.00 per share. The firm cites the proposed deal for the upgrade.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZIMV: